Epilepsy and adolescents

Panminerva Medica

Volumn 45, Issue 4, 2003, Pages 231-240

  Verrotti, A ^a   Di Corcia, G ^a   Morgese, G ^b   Trotta, D ^a   Chiarelli, F ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Adolescence Epilepsy; Complications; Diagnosis Epilepsy

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROTIRELIN; THYROID HORMONE; THYROTROPIN; THYROXINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; ADOLESCENCE; ADOLESCENT; ATTITUDE; BODY WEIGHT; BONE DISEASE; BONE METABOLISM; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG INDICATION; ENDOCRINE FUNCTION; ENDOMETRIUM CARCINOMA; EPILEPSY; FRAGILITY FRACTURE; HEALTH CARE PERSONNEL; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOTHYROIDISM; INFERTILITY; LONG TERM CARE; MENSTRUAL IRREGULARITY; MENTAL DETERIORATION; METABOLIC DISORDER; MOTIVATION; MYOCLONUS EPILEPSY; OBESITY; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; OVARY POLYCYSTIC DISEASE; PARENTAL BEHAVIOR; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTICONVULSANTS; BODY WEIGHT; ENDOCRINE GLANDS; EPILEPSIES, PARTIAL; EPILEPSY; EPILEPSY, ABSENCE; EPILEPSY, TONIC-CLONIC; FEMALE; HUMANS; MALE; MYOCLONIC EPILEPSY, JUVENILE; PATIENT COMPLIANCE; UNITED STATES;

EID: 1542790463     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. American Medical Association. AMA guidelines for adolescent preventive services (GAPS): recommendations and rationale. Baltimore: Williams & Wilkins; 1994.
2. rd ed. Los Angeles: Williams & Wilkins editors; 1996.p.381-99.
3. rd ed. Dublin: Butterworth Heinemann Edition; 1994.
4. Sheth RD. Adolescent issue in epilepsy. JCN 2002;17 Suppl. 2:2S23.
5. Holmes GL, Engel J Jr. Predicting medical intractability of epilepsy in children: how certain can we be? Neurology 2001;56:1430-1.
6. Annegers JF, Dubinsky S, Coan SP, Newmark ME, Roht L. The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia 1999;40:502-6.
7. rd ed. Philadelphia: Lippincott Williams and Wilkins; 2001.p.131-8.
8. Camfield CS, Camfield PR, Gordon K, Wirrell E, Dooley JM. Incidence of epilepsy in childhood and adolescence. A population-based study in Nova Scotia from 1977 to 1985. Epilepsia 1996;37:19-23.
9. Waalance H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2 052 922 and age-specific fertility rates of women with epilepsy. Lancet 1998;352:1970-3.
10. Delgato-Escueta AV, Enrile-Bacsal F. Juvenile myoclonic epilepsy of Janz. Neurology 1984;34:285-94.
11. Dreifuss FE. Juvenile myoclonic epilepsy. Characteristics of primary generalized epilepsy. Epilepsia 1989;30 Suppl 4:S1-7; S24-27.
12. Grunewald RA, Panayiotopoulos CP. Juvenile myoclonic epilepsy. A review. Arch Neurol 1993;50:594-8.
13. Bourgeois B. New antiepileptic drugs in children. Which ones for which seizures? Clin Neuropharmacol 2000;23:119-32.
14. Ojemann LM, Shastri RA, Wilensky AJ, Friel PN, Levy RH, McLean JR et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine and phenytoine monotherapy. Ther Drug Monit 1986;8:293-6.
15. Kumagai N, Seki T, Yamawaki H, Suzuki N, Kimiya S, Yamada T et al. Monotherapy for childhood epilepsies with zonisamide. Jpn J Psychiatr Neurol 1991;45:357-9.
16. Engel J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42:796-803.
17. Gloor P. Generalized epilepsy with spike-and-wave discharge: a reinterpretation of its electrographic and clinical manifestations. The 1977 William G. Lennox Lecture, American Epilepsy Society. Epilepsia 1979;20:571-88.
18. Durner M, Zhou G, Fu D, Abreu P, Shinnar S, Resor SR et al. Evidence for linkage of adolescent-onset idiopathic generalized epilepsies to chromosome 8 and genetic heterogeneity. Am J Hum Genet 1999;64:1411-9.
19. Sander T, Kretz R, Schulz H, Sailer U, Bauer G, Scaramelli A et al. Replication analysis of a putative susceptibility locus (EGI) for idiopathic generalized epilepsy on chromosome 8q24. Epilepsia 1998;39:715-20.
20. Greenberg DA, Durner M, Keddache M, Shinnar S, Resor SR, Moshe SL et al. Reproducibility and complications in gene searches: linkage on chromosome 6, heterogeneity, association, and maternal inheritance in juvenile myoclonic epilepsy. Am J Hum Genet 2000;66:508-16.
21. Liu AW, Delgado-Escueta AV, Gee MN, Serratosa JM, Zhang OW, Alonso ME et al. Juvenile myoclonic epilepsy in chromosome 6p12-p11: locus heteogeneity and recombinations. Am J Med Genet 1996;63:438-46.
22. Durner M, Shinnar S, Resor SR, Moshe SL, Rosenbaum D, Cohen J et al. No evidence for a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. Am J Med Genet 2000;96:49-52.
23. nd ed. London, Paris: John Libbey; 1992.p.151-60.
24. Wolf, P. Juvenile absence epilepsy. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perrett A, Wolf P et al., editors. Epileptic syndromes in infancy, childhood and adolescence. London, Paris: John Libbey; 1992.p.307-12.
25. Cross J. Topiramate monotherapy for children with absence seizures. Results from an open-label pilot study. Epilepsia 1998;39 Suppl 6:164.
26. Bebin M. Pediatric partial and generalized seizures. J Child Neurol 2002;17 Suppl 1:S68.
27. Yeung S, Ferrie CD, Murdoch-Eaton DG, Livingston JM. Topiramate for drug resistant epilepsies. Eur J Paediatr Neurol 2000;4:31-3.
28. Dooley JM, Camfield PR, Smith E, Langevin P, Ronen G. Topiramate in intractable childhood onset epilepsy: a cautionary note. Can J Neurol Sci 1999;26:271-3.
29. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome: Topiramate YL Study Group. Neurology 1999;52:1882-7.
30. Sachdeo RC. Topiramate: clinical profile in epilepsy. Clin Pharmacokinet 1998;34:335-46.
31. Glause TA. Preliminary observations on topiramate in pediatric epilepsies. Epilepsia 1997;34 Suppl 1:S37-41.
32. Bourgeois B. New antiepileptic drugs in children. Which ones for which seizures? Clin Neuropharmacol 2000;23:119-32.
33. Frank LM, Enlow T, Holmes GL, Manasco P, Coneannon S, Chen C et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999;40:973-9.
34. Buoni S, Grosso S, Fois A. Lamotrigine in typical absence epilepsy. Brain Dev 1999;21:303-6.
35. Beran RG, Berkovic SF, Dunagan FM, Vajda FJ, Dante G, Black AB et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalized epilepsy. Epilepsia 1998;39 Suppl 1:1329-33.
36. Mikati MA, Holmes GL. Lamotrigine in absence and primary generalized epilepsies. J Child Neurol 1997;12:S29-37.
37. Dreifuss FE. Lamotrigine in childhood epilepsies. Semin Pediatr Neurol 1997;4:19-23.
38. Gerike CA, Picard F, Saint-Martin A, Strumia S, Marescaur C, Hirsch E. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study. Epileptic Disord 1999;1:159-65.
39. Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998;353:191-206.
40. Janz D. Juvenile myoclonic epilepsy. Epilepsy with impulsive petit mal. Cleve Clin J Med 1989;Suppl 59:S23-33.
41. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9.
42. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5:149-51.
43. Biraben A, Allain H, Scarabin JM, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55:1757-8.
44. Penry JK, Dean JC, Riela AR. Juvenile myoclonic epilepsy: long-term response to therapy. Epilepsia 1989;30 Suppl 4:S19-23.
45. Arunkumar G, Kotogal P, Rothner D. Localization-related epilepsies: simple partial seizures, complex partial seizures, benign focal epilepsy of childhood and epilepsia partialis continua. In: Pellock J, Dodson EW, Bourgeois BF, editors. Pediatric epilepsy duagnosis and therapy. New York: Raven; 2001.p.243-64.
46. Guerreiro MM, Vigoniuis U, Pohlmann H, de Manreza ML, Fejerman N, Antoniuk SA et al. A double-blind controlled clinical trial oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997;27:205-13.
47. Sachdeo RC, Edwards K, Hasegawa H. Safety and efficacy of oxcarbazepine 1 220 mg/day in patients with refractory partial seizures. [Abstract]. Neurology 1999;52 Suppl 2:A391.
48. Schachter SC, Vazquez B, Fisher RS, Laxer KD, Moutouris GD, Combs-Cantrell DT et al. Oxcarbazepine: a double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999;52:732-7.
49. Beydoun A, Sachdeo RC, Rosenfeld WE, Krauss GL, Sessler N, Mesenbrink P. Oxcarbazepine monotherapy for partial-onset seizures. A multicenter, double-blind, clinical trial. Neurology 2000;54:2245-51.
50. Glauser TA, Nigro M, Sachdeo R, Pasteris LA, Weinstein S, Abou-Khalil B et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000;54:2237-44.
51. Glauser TA. Expanding first-line therapy options for children with partial seizures. Neurology 2000;55 Suppl 3:S30-7.
52. Gilliam FG, Reife R, Wu S-C. Topiramate monotherapy. Randomized controlled trial in patients with recently diagnosed localization-related epilepsy [abstract]. Neurology 1999;52 Suppl 2:A248.
53. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. A double-blind, randomized trial of topiramate as adjunctive therapy for partial onset seizures in children. Neurology 1999;52:1338-44.
54. Appleton R, Fichtner K, LaMoreaux L, Alexander J, Halsall G, Murray G et al. Gabapentin as addon therapy in children with refractory partial seizures. A 12 week, multicenter, double-blind, placebo-controlled study. Epilepsia 1999;40:1147-54.
55. Nordli DR Jr. Special needs of the adolescent with epilepsy. Epilepsia 2001;42 Suppl 8:10-7.
56. Kyngas H. Predictors of good compliance in adolescents with epilepsy. Seizure 2001;10:549-53.
57. Kyngas H. Compliance with health regimens of adolescents with epilepsy. Seizure 2000;9:598-604.
58. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-9.
59. Novak GP, Maytal J, Alshansky A, Eviatar L, Sy-Kho R, Siddique O. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999;14:490-5.
60. Devinsky O, Vuong A, Hammer A, Batter PS. Stable weight during lamotrigine therapy. A review of 32 studies. Neurology 2000;54: 973-5.
61. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight changes associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-7.
62. Vorum H, Gram L, Honore B. Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity. Epilepsy Res 1993;16:55-64.
63. Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999;53:230-2.
64. Verrotti A, Domizio S, Angelozzi B, Sabatino G, Morgese G, Chiarelli F. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr Child Health 1997;33:242-5.
65. Verrotti A, Basciani F, Domizio S, Sabatino G, Morgese G, Chiarelli F. Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr Neurol 1998;19:364-7.
66. Carmant L, Holmes GL, Sawyer S, Rifai N, Anderson J, Mikati MA. Efficacy of felbamate in therapy for partial epilepsy in children. J Pediatr 1994;125:481-6.
67. Harden CL, Trifiletti R, Kutt H. Felbamate levels in patients with epilepsy. Epilepsia 1996;37:280-3.
68. Abou-Khalil B. Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group. Epilepsia 2000;41 Suppl 1:S72-6.
69. Roy Chengappa KN, Levine J, Rathore D, Parepally H, Atzert R. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry 2001;16:186-90.
70. Teter CJ, Early JJ, Gibbs CM. Treatment of affective disorder and obesity with topiramate. Ann Pharmacother 2000;34:1262-5.
71. Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KTS, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84.
72. Jouko IT, Isojarvi JI, Timo J, Laatikainen, Knip M, Pakarinen AJ et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84.
73. Stoffel-Wagner B, Bauer J, Flügel, Brennemann W, Klingmüller, Elger CE. Serum sex hormones are altered in patients with chronic temporal lobe epilepsy receiving anticonvulsant medication. Epilepsia 1998;39:1164-73.
74. Macphee GJA, Larkin JG, Butler E, Beastall GH, Brodie MJ. Circulating hormones and pituitary responsiveness young epileptic men receiving long-term antiepileptic medication. Epilepsia 1988;29:468-75.
75. Murialdo G, Galimberti CA, Fonzi S, Manni R, Costelli P, Parodi C et al. Sex hormones and pituitary function in male epileptic patients with altered or normal sexuality. Epilepsia 1995;36:360-5.
76. Morrel MJ. Effects of epilepsy on women's reproductive health. Epilepsia 1998;39 Suppl 8:S32-7.
77. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8.
78. Isojarvi JI, Rattya J, Myllyla VV, Knip M, Koivunen R, Pakarinen AJ et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-51.
79. Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs 2001;15:633-42.
80. Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57:445-9.
81. Pedrera JD, Canal ML, Carvajal J, Postigo S, Villa LF, Hernandez ER et al. Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. Eur J Clin Invest 2000;30:895-9.
82. Kafali G, Erselcan T, Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr 1999;38:93-8.
83. Tsukahara H, Kimura K, Todoroki Y, Ohshima Y, Hiraoka M, Shigematsu Y et al. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 2002;44:247-53.
84. Verotti A, Greco R, Morgese G, Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000;47:385-8.
85. Stephen LJ, McLellan AR, Harrison JH, Shapiro D, Dominiczak MH, Sills GJ et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999;8:339-42.
86. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-53.
87. Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA. Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000;108:37-43.
88. Isojarvi JI, Turkka J, Pakarinen AJ, Kotila M, Rattya J, Myllyla VV. Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia 2001;42:930-4.
89. Larkin JG, MacPhee GJA, Beastall GH, Brodie MJ. Thyroid hormone concentrations in epileptic patients. Eur J Clin Pharmacol 1989;36:213-6.
90. Haidukewych D, Rodin EA. Chronic antiepileptic drug therapy. Classification by medication regimen and incidence of decreases in serum thyroxine and free thyroxine index. Ther Drg Monit 1987;9:392-8.
91. Tanaka K, Kodama S, Yokoyama S, Komatsu M, Konishi H, Momota K et al. Thyroid function in children with long-term anticonvulsant treatment. Pediatr Neurosci 1987;13:90-4.
92. Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F. Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatr Neurol 2001;25:43-6.
93. Eiris-Punal J, Del Rio-Garma M, Del Rio-Garma MC, Lojo-Rocamode S, Novo-Rodriguez I, Castro-Gago M. Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia 1999;40:1761-6.